Literature DB >> 34343220

A systematic review and meta-analysis on international studies of prevalence, mortality and survival due to coal mine dust lung disease.

Cynthia Lu1, Paramita Dasgupta1, Jessica Cameron1,2, Lin Fritschi3, Peter Baade1,2,4.   

Abstract

BACKGROUND: Coal mine dust lung disease comprises a group of occupational lung diseases including coal workers pneumoconiosis. In many countries, there is a lack of robust prevalence estimates for these diseases. Our objective was to perform a systematic review and meta-analysis of published contemporary estimates on prevalence, mortality, and survival for coal mine dust lung disease worldwide.
METHODS: Systematic searches of PubMed, EMBASE and Web of Science databases for English language peer-reviewed articles published from 1/1/2000 to 30/03/2021 that presented quantitative estimates of prevalence, mortality, or survival for coal mine dust lung disease. Review was conducted per PRISMA guidelines. Articles were screened independently by two authors. Studies were critically assessed using Joanna Briggs Institute tools. Pooled prevalence estimates were obtained using random effects meta-analysis models. Heterogeneity was measured using the I2 statistics and publication bias using Egger's tests.
RESULTS: Overall 40 studies were included, (31 prevalence, 8 mortality, 1 survival). Of the prevalence estimates, fifteen (12 from the United States) were retained for the meta-analysis. The overall pooled prevalence estimate for coal workers pneumoconiosis among underground miners was 3.7% (95% CI 3.0-4.5%) with high heterogeneity between studies. The pooled estimate of coal workers pneumoconiosis prevalence in the United States was higher in the 2000s than in the 1990s, consistent with published reports of increasing prevalence following decades of declining trends. Sub-group analyses also indicated higher prevalence among underground miners, and in Central Appalachia. The mortality studies were suggestive of reduced pneumoconiosis mortality rates over time, relative to the general population.
CONCLUSION: The ongoing prevalence of occupational lung diseases among contemporary coal miners highlights the importance of respiratory surveillance and preventive efforts through effective dust control measures. Limited prevalence studies from countries other than the United States limits our understanding of the current disease burden in other coal-producing countries.

Entities:  

Year:  2021        PMID: 34343220      PMCID: PMC8330946          DOI: 10.1371/journal.pone.0255617

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  53 in total

1.  Radiographic outcomes among South African coal miners.

Authors:  Rajen N Naidoo; Thomas G Robins; A Solomon; Neil White; Alfred Franzblau
Journal:  Int Arch Occup Environ Health       Date:  2004-09-09       Impact factor: 3.015

2.  Radiographic disease progression in contemporary US coal miners with progressive massive fibrosis.

Authors:  A Scott Laney; David John Blackley; Cara N Halldin
Journal:  Occup Environ Med       Date:  2017-04-13       Impact factor: 4.402

3.  Mortality among U.S. underground coal miners: a 23-year follow-up.

Authors:  M D Attfield; E D Kuempel
Journal:  Am J Ind Med       Date:  2008-04       Impact factor: 2.214

4.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

5.  Continued increase in prevalence of r-type opacities among underground coal miners in the USA.

Authors:  Noemi B Hall; David J Blackley; Cara N Halldin; A Scott Laney
Journal:  Occup Environ Med       Date:  2019-04-25       Impact factor: 4.402

6.  Silicosis screening in surface coal miners--Pennsylvania, 1996-1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2000-07-14       Impact factor: 17.586

Review 7.  Coal mine dust lung disease in the modern era.

Authors:  Jennifer L Perret; Brian Plush; Philippe Lachapelle; Timothy S C Hinks; Clare Walter; Philip Clarke; Louis Irving; Pat Brady; Shyamali C Dharmage; Alastair Stewart
Journal:  Respirology       Date:  2017-03-30       Impact factor: 6.424

Review 8.  Global burden of COPD: systematic review and meta-analysis.

Authors:  R J Halbert; J L Natoli; A Gano; E Badamgarav; A S Buist; D M Mannino
Journal:  Eur Respir J       Date:  2006-04-12       Impact factor: 16.671

9.  Prevalence Characteristics of Coal Workers' Pneumoconiosis (CWP) in a State-Owned Mine in Eastern China.

Authors:  Lei Han; Ruhui Han; Xiaoming Ji; Ting Wang; Jingjin Yang; Jiali Yuan; Qiuyun Wu; Baoli Zhu; Hengdong Zhang; Bangmei Ding; Chunhui Ni
Journal:  Int J Environ Res Public Health       Date:  2015-07-10       Impact factor: 3.390

Review 10.  Respiratory surveillance for coal mine dust and artificial stone exposed workers in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand.

Authors:  Jennifer L Perret; Susan Miles; Fraser Brims; Katrina Newbigin; Maggie Davidson; Hubertus Jersmann; Adrienne Edwards; Graeme Zosky; Anthony Frankel; Anthony R Johnson; Ryan Hoy; David W Reid; A William Musk; Michael J Abramson; Bob Edwards; Robert Cohen; Deborah H Yates
Journal:  Respirology       Date:  2020-10-13       Impact factor: 6.424

View more
  3 in total

1.  Experimental and Molecular Dynamics Simulation Study for Preferring Coal Dust Wetting Agents.

Authors:  Liying Sun; Shaocheng Ge; Shuo Liu; Deji Jing; Xi Chen
Journal:  ACS Omega       Date:  2022-05-18

2.  Differences in the characteristics and pulmonary toxicity of nano- and micron-sized respirable coal dust.

Authors:  Yinci Zhang; Amin Li; Jiafeng Gao; Jiaojiao Liang; Niandie Cao; Shuping Zhou; Xiaolong Tang
Journal:  Respir Res       Date:  2022-07-30

3.  Requirement of preoperative blood typing for cholecystectomy and appendectomy: a systematic review.

Authors:  Michael G Fadel; Ishaan Patel; Lawrence O'Leary; Nebil Behar; James Brewer
Journal:  Langenbecks Arch Surg       Date:  2022-07-02       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.